Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508329 | 0.95 | KCNH2 (0.41) | KCNH2PGRKDM1A | |
| SCHEMBL4114900 | 0.88 | KDM4E (0.35) | PGRKDM1A | |
| SCHEMBL509380 | 0.87 | KCNH2 (0.34) | KCNH2PGRKDM1A | |
| SCHEMBL508735 | 0.87 | KCNH2 (0.45) | KCNH2PGRKDM1A | |
| SCHEMBL6626980 | 0.83 | PGR (0.33) | PGRKDM1A | |
| SCHEMBL3133937 | 0.82 | KCNH2 (0.36) | KCNH2PGRKDM1ACYP3A4 | |
| SCHEMBL508818 | 0.80 | PGR (0.41) | KCNH2PGRKDM1A | |
| SCHEMBL5157248 | 0.80 | KDM4C (0.34) | KCNH2PGR | |
| SCHEMBL10250663 | 0.78 | PGR (0.32) | PGR | |
| SCHEMBL10250624 | 0.78 | KCNH2 (0.37) | KCNH2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542679-B1 | 4-(3,5-DICYANOPHENOXY) PYRAZOLE DERIVATIVES FOR USE AS TRANSCRIPTASE MODULATORS IN THE TREATMENT OF I.A. HIV | PFIZER LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| EP-1542679-B1 | 4-(3,5-DICYANOPHENOXY) PYRAZOLE DERIVATIVES FOR USE AS TRANSCRIPTASE MODULATORS IN THE TREATMENT OF I.A. HIV | PFIZER LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| US-20040132793-A1 | Pyrazole derivatives | PFIZER INC. | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132793-A1 | Pyrazole derivatives | POLA1, REV1, POLR2E | KCNH2 3447/4885PGR 705/4885KDM1A 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.